Cargando…

Advancements in the treatment of metastatic hormone-sensitive prostate cancer

In the last decade, there have been substantial improvements in the outcome of the management of metastatic hormone-sensitive prostate cancer (mHSPC) following the development of several novel agents as well as by combining several therapeutic strategies. Although the overall survival (OS) of mHSPC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hengping, Zhang, Mao, Wang, Xiangrong, Liu, Yang, Li, Xuanpeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433581/ https://www.ncbi.nlm.nih.gov/pubmed/36059610 http://dx.doi.org/10.3389/fonc.2022.913438

Ejemplares similares

Application of machine learning algorithm in prediction of lymph node metastasis in patients with intermediate and high-risk prostate cancer
por: Wang, Xiangrong, et al.
Publicado: (2023)

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients
por: Sigurdson, Samantha S., et al.
Publicado: (2020)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer
por: Sung, Winnie W. Y., et al.
Publicado: (2021)

Comparison of doublet and triplet therapies for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis
por: Wang, Lei, et al.
Publicado: (2023)

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies
por: Wenzel, Mike, et al.
Publicado: (2021)

Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China
por: Zhang, Yang, et al.
Publicado: (2023)

Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis
por: Chen, Junru, et al.
Publicado: (2020)

Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial
por: Yang, Dingyuan, et al.
Publicado: (2023)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis
por: Matsumura, Naoki, et al.
Publicado: (2021)

Comparative Efficacy of Combined Radiotherapy, Systemic Therapy, and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis and Systematic Review
por: Wang, Yuhan, et al.
Publicado: (2020)

Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
por: Muniyan, Sakthivel, et al.
Publicado: (2022)

Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?
por: Davis, Ian D.
Publicado: (2022)

Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
por: Chen, Kenneth, et al.
Publicado: (2022)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
por: Ng, Kenrick, et al.
Publicado: (2020)

Metastatic prostate tumor to testes: Sign of advance disease
por: Ahmed, Syed Adeel, et al.
Publicado: (2023)

Case report of metastatic prostate cancer to testicles: An ominous sign of advanced disease
por: Turk, Andrew, et al.
Publicado: (2019)

Which Way to Choose for the Treatment of Metastatic Prostate Cancer: A Case Report and Literature Review
por: Yang, Xiangwei, et al.
Publicado: (2021)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy
por: Yang, Guanjie, et al.
Publicado: (2022)

Overall survival and cancer-specific survival were improved in local treatment of metastatic prostate cancer
por: Miao, Qi, et al.
Publicado: (2023)

Progression in immunotherapy for advanced prostate cancer
por: Liang, Hao, et al.
Publicado: (2023)

Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer
por: Inaba, Koji, et al.
Publicado: (2021)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers
por: Kong, Yuehong, et al.
Publicado: (2021)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

Multimodal therapy in the treatment of metastatic prostate cancer: A case report
por: Omidele, Olamide O., et al.
Publicado: (2018)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
por: Shenoy, Niraj, et al.
Publicado: (2016)

Metastatic hormone-sensitive prostate cancer: How should it be treated?
por: López-Campos, Fernando, et al.
Publicado: (2021)

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Survival in Patients With Metastatic Prostate Cancer Undergoing Radiotherapy: The Importance of Prostate-Specific Antigen-Based Stratification
por: Tian, Zijian, et al.
Publicado: (2021)

Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen
por: Rathore, Rajni, et al.
Publicado: (2023)

Case Report: Tumor-to-tumor metastasis with prostate cancer metastatic to lung cancer: the first reported case
por: Liu, Shiyue, et al.
Publicado: (2023)

Molecular Characterization and Clinical Relevance of N(6)-Methyladenosine Regulators in Metastatic Prostate Cancer
por: Liu, Qiwei, et al.
Publicado: (2022)

Treatment Intensification for Low-risk Metastatic Hormone-sensitive Prostate Cancer: The Time Is Now
por: McKay, Rana R.
Publicado: (2022)

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wang, Jiaxin, et al.
Publicado: (2020)

Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer
por: Briones, Juan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8rg5alkecipjkl2njbpji51f28